171 related articles for article (PubMed ID: 24610228)
1. Propranolol in infantile haemangioma: simplifying pretreatment monitoring.
El Ezzi O; Hohlfeld J; de Buys Roessingh A
Swiss Med Wkly; 2014 Mar; 144():w13943. PubMed ID: 24610228
[TBL] [Abstract][Full Text] [Related]
2. Safety profile during initiation of propranolol for treatment of infantile haemangiomas in an ambulatory day-care hospitalization setting.
Fogel I; Ollech A; Zvulunov A; Valdman-Greenshpon Y; Atar Snir V; Friedland R; Lapidoth M; Ben-Amitai D
J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):2004-2009. PubMed ID: 29573481
[TBL] [Abstract][Full Text] [Related]
3. A new treatment pathway for propranolol use in infantile haemangiomas.
May JE; Liew SH
J Plast Reconstr Aesthet Surg; 2014 Mar; 67(3):e91-2. PubMed ID: 24268691
[No Abstract] [Full Text] [Related]
4. Consensus statement for the treatment of infantile haemangiomas with propranolol.
Smithson SL; Rademaker M; Adams S; Bade S; Bekhor P; Davidson S; Dore A; Drummond C; Fischer G; Gin A; Grills C; Halbert A; Lokmic Z; McCahon E; Morgan VA; Murrell DF; Orchard D; Penington A; Purvis D; Relic J; Robertson S; Robinson AJ; Scardamaglia L; Su J; Tan S; Wargon O; Warren L; Wong LC; Zappala T; Phillips R
Australas J Dermatol; 2017 May; 58(2):155-159. PubMed ID: 28251611
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Infantile Haemangioma - Perspective of a Regional Surgical Centre.
Ho W; Hoo C; Black C
Ulster Med J; 2019 May; 88(2):102-104. PubMed ID: 31061558
[No Abstract] [Full Text] [Related]
6. PHACE syndrome, a series of six patients: clinical and morphological manifestations, propranolol efficacy, and safety.
Bellaud G; Puzenat E; Billon-Grand NC; Humbert P; Aubin F
Int J Dermatol; 2015 Jan; 54(1):102-7. PubMed ID: 24962639
[TBL] [Abstract][Full Text] [Related]
7. Treatment with propranolol for infantile hemangiomas: single-center experience.
Turhan AB; Bör Ö; Özdemir ZC
J Cosmet Dermatol; 2016 Sep; 15(3):296-302. PubMed ID: 27061310
[TBL] [Abstract][Full Text] [Related]
8. Treatment of severe infantile hemangiomas with propranolol: an evaluation of the efficacy and effects of cardiovascular parameters in 25 consecutive patients.
Xu DP; Cao RY; Xue L; Sun NN; Tong S; Wang XK
J Oral Maxillofac Surg; 2015 Mar; 73(3):430-6. PubMed ID: 25544304
[TBL] [Abstract][Full Text] [Related]
9. Treatment of problematic infantile hemangiomas with propranolol: a series of 40 cases and review of the literature.
Oksiuta M; Matuszczak E; Dębek W; Dzienis-Koronkiewicz E; Hermanowicz A; Tylicka M
Postepy Hig Med Dosw (Online); 2014 Sep; 68():1138-44. PubMed ID: 25228522
[TBL] [Abstract][Full Text] [Related]
10. Infantile hemangioma: treatment with short course systemic corticosteroid therapy as an alternative for propranolol.
Nieuwenhuis K; de Laat PC; Janmohamed SR; Madern GC; Oranje AP
Pediatr Dermatol; 2013; 30(1):64-70. PubMed ID: 22958179
[TBL] [Abstract][Full Text] [Related]
11. Cardiac side effects of propranolol in infants treated for infantile haemangiomas.
Maliqari N; Duka E; Kuneshka L
Cardiol Young; 2023 Dec; 33(12):2616-2620. PubMed ID: 37078179
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the effectiveness of topical propranolol 4% gel for infantile hemangiomas.
Mashiah J; Kutz A; Rabia SH; Ilan EB; Goldberg I; Sprecher E; Harel A
Int J Dermatol; 2017 Feb; 56(2):148-153. PubMed ID: 28074521
[TBL] [Abstract][Full Text] [Related]
13. Parental experiences with propranolol versus oral corticosteroids for complicated infantile hemangioma, a retrospective questionnaire study.
Hermans DJ; Zweegers J; Evers AW; Van Der Vleuten CJ
Eur J Dermatol; 2013; 23(6):857-63. PubMed ID: 24185746
[TBL] [Abstract][Full Text] [Related]
14. Propranolol therapy in 55 infants with infantile hemangioma: dosage, duration, adverse effects, and outcome.
Schupp CJ; Kleber JB; Günther P; Holland-Cunz S
Pediatr Dermatol; 2011; 28(6):640-644. PubMed ID: 21995836
[TBL] [Abstract][Full Text] [Related]
15. Propranolol treatment of infantile hemangioma (IH) is not associated with developmental risk or growth impairment at age 4 years.
Moyakine AV; Kerstjens JM; Spillekom-van Koulil S; van der Vleuten CJ
J Am Acad Dermatol; 2016 Jul; 75(1):59-63.e1. PubMed ID: 27021240
[TBL] [Abstract][Full Text] [Related]
16. Refractive and structural changes in infantile periocular capillary haemangioma treated with propranolol.
Snir M; Reich U; Siegel R; Zvulunov A; Friling R; Goldenberg-Cohen N; Ron Y; Ben-Amitay D
Eye (Lond); 2011 Dec; 25(12):1627-34. PubMed ID: 21921959
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with delayed referral for infantile hemangioma necessitating propranolol.
Onnis G; Dreyfus I; Mazereeuw-Hautier J
J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1584-1588. PubMed ID: 29405477
[TBL] [Abstract][Full Text] [Related]
18. Low-dose propranolol regimen for infantile haemangioma.
Tan CE; Itinteang T; Leadbitter P; Marsh R; Tan ST
J Paediatr Child Health; 2015 Apr; 51(4):419-24. PubMed ID: 25187156
[TBL] [Abstract][Full Text] [Related]
19. Experience with Holter monitoring during propranolol therapy for infantile hemangiomas.
Jacks SK; Kertesz NJ; Witman PM; Fernandez Faith E
J Am Acad Dermatol; 2015 Aug; 73(2):255-7. PubMed ID: 26054433
[TBL] [Abstract][Full Text] [Related]
20. Outpatient use of oral propranolol and topical timolol for infantile hemangiomas: survey results and comparison with propranolol consensus statement guidelines.
Kumar MG; Coughlin C; Bayliss SJ
Pediatr Dermatol; 2015; 32(2):171-9. PubMed ID: 25556828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
